Edesa Biotech, Inc. (EDSA): Price and Financial Metrics
GET POWR RATINGS... FREE!
EDSA Stock Price Chart Interactive Chart >
EDSA Price/Volume Stats
| Current price | $1.48 | 52-week high | $12.00 |
| Prev. close | $1.47 | 52-week low | $1.40 |
| Day low | $1.40 | Volume | 80,400 |
| Day high | $1.53 | Avg. volume | 76,252 |
| 50-day MA | $1.96 | Dividend yield | N/A |
| 200-day MA | $4.55 | Market Cap | 22.88M |
Edesa Biotech, Inc. (EDSA) Company Bio
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Latest EDSA News From Around the Web
Below are the latest news stories about Edesa Biotech Inc that investors may wish to consider to help them evaluate EDSA as an investment opportunity.
EDSA: Phase 3 Trial of EB05 Hits 25% Enrollment…By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Phase 3 Trial of EB05 Hits 25% Enrollment On February 17, 2022, Edesa Biotech, Inc. (NASDAQ:EDSA) announced that more than 25% of the subjects have been randomized under the Phase 3 protocol approved by Health Canada for the ongoing clinical trial of EB05 for the treatment of acute respiratory distress syndrome |
Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS StudyTORONTO, ON / ACCESSWIRE / February 17, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an update on the Phase 3 part of a Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate, designated EB05, as a single-dose therapy for hospitalized Covid-19 patients. |
Edesa Biotech Reports Fiscal 1st Quarter 2022 ResultsTORONTO, ON / ACCESSWIRE / February 14, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2021 and provided an update on its business. |
When Can We Expect A Profit From Edesa Biotech, Inc. (NASDAQ:EDSA)?Edesa Biotech, Inc. ( NASDAQ:EDSA ) is possibly approaching a major achievement in its business, so we would like to... |
Edesa Biotech to Join Ontario Bioscience Panel DiscussionTORONTO, ON / ACCESSWIRE / January 26, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. |
EDSA Price Returns
| 1-mo | -28.16% |
| 3-mo | -49.66% |
| 6-mo | -73.71% |
| 1-year | -71.97% |
| 3-year | -79.27% |
| 5-year | -97.11% |
| YTD | -73.71% |
| 2021 | 32.47% |
| 2020 | 3.66% |
| 2019 | -24.91% |
| 2018 | -83.95% |
| 2017 | -60.10% |
Loading social stream, please wait...